SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as a potential solution to increase transaction speeds and enhance regulatory compliance in blockchain, with some community members suggesting it could complement larger crypto projects like NVDA, SUI, and BTC. Its focus on institutional financial infrastructure and integrations with companies like Stripe are also key talking points. However, some users express concern regarding the project.

Americas Gold & Silver Corp. engages in the acquisition, exploration, development, and exploration of mineral resource properties. It operates through the following segments: Cosalá Operations, Galena Complex, Relief Canyon, and Corporate and Other. The Cosalá Operations segment operates in Mexico. The Galena Complex and Relief Canyon segments focuses on the United States. The company was founded by Peter Jude Hawley on May 12, 1998 and is headquartered in Toronto, Canada.

Americas Gold and Silver Corp

Americas Silver Corp

Americas Silver Corp is trending as silver prices surge, sparking discussions about the company's potential growth and profitability. Community members are focused on its antimony production and the possibility of government funding, as well as speculation regarding future mergers and acquisitions. The rising silver prices and the company's strategic positioning are creating optimism about its long-term prospects.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors discuss the potential impact of a move to the Nasdaq exchange and speculate about upcoming OEM partnerships, particularly with the inauguration of the Eagle Line facility approaching in February 2026. The community's focus is on the company's technology, scaling roadmap, and anticipated announcements, with bullish investors expressing confidence in QuantumScape's long-term potential in the solid-state battery market.

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is trending as community members discuss its potential alongside emerging Layer 1 solutions like Keeta, particularly regarding high-throughput capabilities and institutional adoption. Community talking points highlight Avalanche's subnet architecture versus Keeta's focus on compliance-ready financial infrastructure. Keeta's integration with Stripe's Bridge for fiat on/off-ramps is also sparking interest as a catalyst for institutional flows.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending as its community rallies around its meme-focused culture and energetic online presence, emphasizing the "infection" and "pressure" it brings to the Solana ecosystem. The community is actively spreading memes and expressing excitement about its potential, aiming to bring fun and energy to the crypto space, with some even touting it as a top meme coin for 2026. Discussions highlight the coin's strong community and the "viral" spread of its memes.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token is trending as community members rally behind the token's potential within the Ethereum ecosystem, citing a long-term prophecy and strong community support. Social media buzz suggests growing confidence and anticipation for significant expansion, with some drawing comparisons to other successful meme coins. The community emphasizes the token's role in the broader ETH narrative, attracting attention from traders.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending as investors discuss its potential role in powering AI data centers using natural gas and carbon capture technology, particularly following positive mentions from ExxonMobil's recent earnings call. Community members are weighing the company's prospects against competitors like Bloom Energy, with some anticipating significant upside if FCEL secures major contracts in the expanding AI energy market. Discussions also include the stock's volatile history and the impact of past dilutions on its current valuation.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation that cannabis could be reclassified, potentially easing tax burdens and banking restrictions for cannabis companies. The community is discussing potential price targets and whether this rally has staying power, with some citing historical runs and short squeeze potential. However, some caution against hype, noting the reverse stock split and potential for dilution.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as community members discuss its interoperability, while some suggest Keeta ($KTA) as a potentially undervalued alternative, citing its high throughput and institutional connections. Discussions highlight Polkadot's role in connecting blockchains, with some viewing Keeta as complementary infrastructure for regulated financial flows. The community is actively comparing the potential benefits and drawbacks of each network, focusing on compliance, throughput, and institutional adoption.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as investors react to speculation around potential federal cannabis policy changes, including a possible executive order from President Trump. Community members are discussing the implications of rescheduling for US cannabis companies and whether this time could be different after years of false starts. Talk centers on potential catalysts like the Supreme Court taking up the cannabis case and the impact on profitability due to tax code changes.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX

683 Capital Management LLC grew its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 126.9% during the second quarter, according to the company in its most recent 13F filing with...

Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC lessened its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 44.3% in the second quarter, according to the company in its most recent Form 13F...

Kennondale Capital Management LLC Sells 94,551 Shares of Aldeyra Therapeutics, Inc. $ALDX

Kennondale Capital Management LLC trimmed its holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 62.5% in the second quarter, according to its most recent disclosure with the...

Savant Capital LLC Makes New $552,000 Investment in Aldeyra Therapeutics, Inc. $ALDX

Savant Capital LLC bought a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission...

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at...

Aldeyra Therapeutics (NASDAQ:ALDX) Given Buy Rating at BTIG Research

BTIG Research reissued a "buy" rating and issued a $9.00 price target on shares of Aldeyra Therapeutics in a report on Monday...

Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced...

Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the...

<ul class="summary-bullets"><li>ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study.</li><li>Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said.&nbsp;</li><li>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome.&nbsp; &nbsp;</li></ul>Aldeyra Therapeutics, Inc. (ALDX) on Tuesday announced that its experimental drug candidate ADX-629 demonstrated statistically significant improvement in liver function in patients with alcohol-associated hepatitis in a mid-stage trial.ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study. Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-phase-2-clinical">said.</a>No serious adverse events were reported in the trial, the company noted. Furthermore, no adverse events were deemed related to its experimental drug, it added.<h2 class="st-heading-2">Plans Ahead</h2>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome, a rare genetic disorder.CEO Todd C. Brady said that the company will share details of the recent trial in the future and will now focus its pipeline on ADX-248 and ADX-246 for the treatment of immune-mediated diseases.While ADX-248 is being studied in the treatment of metabolic inflammation, including obesity and hypertriglyceridemia, ADX-246 is being studied for the treatment of dry form of age-related macular degeneration.Aldeyra is committed to developing a robust pipeline of novel therapeutics in a fiscally prudent manner to maintain growth, the CEO noted.The company now expects cash, cash equivalents, and marketable securities to provide operational runway into the second half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.ALDX stock is down by 0.5% this year and by about 12% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-registrations-slumped-nearly-19-percent-in-eu-in-september-despite-rising-ev-demand/cLGjW7LR3HL">Tesla Registrations Slumped Nearly 19% In EU In September Despite Rising EV Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development

Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said. 

Equity

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.16	--	--	N/A
Q3 '25	-$0.13	--	--	N/A
Q2 '25	-$0.19	-$0.16	14.29%	BEAT
Q1 '25	-$0.27	--	--	N/A
Q4 '24	-$0.26	--	--	N/A

ALDX
Aldeyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ALDX News

ALDXAldeyra Therapeutics Inc